Kepakemapa 8, 2025, ua hoʻolaha ʻo InnoCare Pharma ua ʻāpono ʻia ʻo HIBRUKA (orelabrutinib) e ka Health Sciences Authority (HSA) o Singapore no ka mālama ʻana i nā poʻe maʻi makua me ka relapsed a i ʻole refractory marginal zone lymphoma (R/R MZL).
I kēia manawa, nui nā hoʻokolohua lapaʻau o nā ʻenehana anti-cancer hou ma Kina e ʻimi nei i nā maʻi. I ke kūkākūkā ʻana i nā lāʻau lapaʻau a me nā ʻenehana hou, hiki iā ʻoe ke hoʻokaʻaʻike aku i ka Beijing South Region Oncology Hospital International Department.
Helu Kelepona：4008803716
ʻIkepili WeChat: 17801183037
Email：myimmnet@163.com
ʻO ka marginal zone lymphoma (MZL) kahi indolent B-cell non-Hodgkin's lymphoma (NHL) e hoʻopilikia nui ana i nā poʻe maʻi waena a me nā poʻe ʻelemakule. Ke piʻi nei ka nui o ka MZL i kēlā me kēia makahiki ma ka honua holoʻokoʻa. Ma hope o ka mālama mua ʻana, ʻaʻohe o nā koho lapaʻau kūpono i nā poʻe maʻi me R/R MZL.
I ʻApelila 2025, ua ʻae ʻia ka orelabrutinib ma Kina no ka mālama mua ʻana i nā maʻi me ka leukemia lymphocytic mau loa (CLL) / lymphoma lymphocytic liʻiliʻi (SLL). Ua ʻae ʻia hoʻi ʻo Orelabrutinib no ka mālama ʻana i ʻekolu mau hōʻailona ʻē aʻe ma Kina, me ka relapsed and refractory (R/R) CLL/SLL, r/r mantle cell lymphoma (R/R MCL) a me r/r marginal zone lymphoma (R/R MZL), a ua uhi ʻia nā mea a pau ma ka National Reimbursement Drug List o Kina.
ʻO ka Pono, ka Palekana, a me ke Kumumanaʻo o Orelabrutinib Plus Obinutuzumab ma Systemic Treatment-Naive Marginal Zone Lymphoma: Ua hōʻike ʻia kahi Prospective Cohort Study ma ke aʻo holoʻokoʻa a i ka wā o ka induction therapy, ʻo ka helu pane holoʻokoʻa (ORR) he 100%. ʻEkolu mau maʻi me ka pane hapa (PR) ma hope o ka induction therapy i loaʻa ka pane piha (CR) i ka wā mālama.
Ua hōʻike nā hoʻāʻo ADCC i ka orelabrutinib i hui pū ʻia me ka regimen obinutuzumab i hoʻoulu i ka pane ADCC ikaika loa ma nā laina cell TMD-8 a me REC-1.
I kēia manawa, nui nā hoʻokolohua lapaʻau o nā ʻenehana anti-cancer hou ma Kina e ʻimi nei i nā maʻi. I ke kūkākūkā ʻana i nā lāʻau lapaʻau a me nā ʻenehana hou, hiki iā ʻoe ke hoʻokaʻaʻike aku i ka Beijing South Region Oncology Hospital International Department.
Helu Kelepona：4008803716
ʻIkepili WeChat: 17801183037
Email：myimmnet@163.com
Ka manawa hoʻouna: Sep-09-2025